Journal
CANCER CELL INTERNATIONAL
Volume 21, Issue 1, Pages -Publisher
BMC
DOI: 10.1186/s12935-020-01739-1
Keywords
-
Categories
Funding
- Dali Tong Chongqing Science and Technology Commission (Basic and Frontier Research Project) [cstc2018jcyjA2133]
- Chongqing Municipal Health and Health Committee (Science and Health Combined Medical Research Project) [2018QNXM041]
Ask authors/readers for more resources
Castration-resistant prostate cancer (CRPC) is still a bottleneck in prostate cancer research and treatment, with abnormal androgen receptor (AR) activation playing a crucial role. The production of overabundant AR-V7 mRNA splicing is currently a focus of study, but there is no definite conclusion about its regulation. Recent research has shown that JMJD6 and U2AF65 may be a promising approach in mRNA splicing regulation.
Castration-resistant prostate cancer (CRPC) remains prostate cancer research and treatment bottleneck. Abnormal androgen receptor (AR) activation still has a pivotal role in CRPC. Multiple mechanisms involve the process, of which overabundant AR-V7 mRNA splicing production is currently focused and increasingly studied. However, factually, there is no definite conclusion about regulation of AR-V7 mRNA splicing. Recently developed knowledge has demonstrated that JMJD6 and U2AF65 as a hopeful approach in mRNA splicing regulation. The authors propose a novel possible mechanism elucidating AR mRNA splicing for CRPC progression using dual-function enzyme JMJD6 and its induced JMJD6/U2AF65/AR-V7 axis. In this hypothesis JMJD6 introduces to AR promoter to demethylate H3R or H4R and promotes AR mRNA transcription via its demethylase activity and interaction with U2AF65. It is expected that JMJD6 could further effectively perform U2AF65 hydroxylation to achieve AR-V7 mRNA splicing via its hydroxylase activity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available